MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria
Journal
Cancer Medicine
Journal Volume
9
Journal Issue
13
Pages
4512-4526
Date Issued
2020
Author(s)
Yassin M.A.
Taher A.
Mathews V.
Shamsi T.
Tuğlular T.F.
Xiao Z.
Kim S.-J.
Depei W.
Li J.
Rippin G.
Sadek I.
Siddiqui A.
Wong R.S.
Abstract
Philadelphia chromosome-negative (Ph?) myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders of the bone marrow, and are associated with a high disease burden, reduced quality of life (QOL), and shortened survival. This multinational, multicenter, non-interventional registry “MERGE” was initiated with an objective to collect data on the epidemiological indices of classical Ph-MPNs, existing treatment patterns, and impact of MPNs on health-related QOL in various countries/regions in Asia, including the Middle East, Turkey, and Algeria. Of the 884 eligible patients with MPNs, 169 had myelofibrosis (MF), 301 had polycythemia vera (PV), 373 had essential thrombocythemia (ET), and 41 had unclassified MPNs. The median age was 58?years (range, 47-66?years), and 50% of patients were males. The prevalence and incidence of MPNs were estimated to be 57-81 and 12-15 per 100?000 hospital patients per year over the last 4?years, respectively, in these countries. Total symptom score (mean [standard deviation; SD]) at baseline was highest in patients with MF (23.5 [17.47]) compared with patients with ET (14.6 [14.26]) and PV (16.6 [14.84]). Patients with ET had a lower mean (SD) number of inpatient visits (0.9 [0.77] days), and patients with MF had more outpatient visits (5.2 [3.17] days) on an average, compared with the entire MPN group. The study showed that patients with MPNs have a severe disease burden and reduced QOL. A discordance between physician and patient perception of symptom assessment was observed in this study?(International clinical?trials registry ID: CTRI/2014/05/004598). ? 2020 The Authors and Novartis Pharma AG. Cancer Medicine published by John Wiley & Sons Ltd.
Subjects
epidemiology; myeloproliferative disorders; neoplasms; quality of life
SDGs
Other Subjects
acetylsalicylic acid; anagrelide; hydroxyurea; interferon; Janus kinase inhibitor; adult; aged; Algeria; Article; cancer incidence; controlled study; disease association; disease burden; female; human; major clinical study; male; Middle East; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; priority journal; quality of life; questionnaire; scoring system; thrombocythemia; treatment duration; trend study; Turkey (republic); Asia; bone marrow; clinical trial; disease exacerbation; incidence; middle aged; multicenter study; myeloid metaplasia; myeloproliferative disorder; pathology; patient attitude; polycythemia vera; prevalence; prospective study; register; splenomegaly; symptom assessment; thrombocythemia; turkey (bird); Aged; Algeria; Asia; Bone Marrow; Disease Progression; Female; Humans; Incidence; Male; Middle Aged; Myeloproliferative Disorders; Patient Acceptance of Health Care; Polycythemia Vera; Prevalence; Primary Myelofibrosis; Prospective Studies; Quality of Life; Registries; Splenomegaly; Symptom Assessment; Thrombocythemia, Essential; Turkey
Publisher
Blackwell Publishing Ltd
Type
journal article